BR112018072263A2 - métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13 - Google Patents

métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13

Info

Publication number
BR112018072263A2
BR112018072263A2 BR112018072263-4A BR112018072263A BR112018072263A2 BR 112018072263 A2 BR112018072263 A2 BR 112018072263A2 BR 112018072263 A BR112018072263 A BR 112018072263A BR 112018072263 A2 BR112018072263 A2 BR 112018072263A2
Authority
BR
Brazil
Prior art keywords
activity
methods
treating diseases
antibodies
harmful
Prior art date
Application number
BR112018072263-4A
Other languages
English (en)
Inventor
Timony Gregg
Gujrathi Sheila
Peach Robert
Olson Allan
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of BR112018072263A2 publication Critical patent/BR112018072263A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Abstract

a presente invenção refere-se a métodos para o tratamento de doenças nas quais a atividade da il-13 é prejudicial, incluindo esofagite eosinofílica (eoe) e asma, através de administrar a um indivíduo em necessidade de tal tratamento, uma composição contendo um anticorpo anti-interleucina-13 (il-13), ou um seu fragmento de ligação ao antígeno.
BR112018072263-4A 2016-04-27 2017-04-27 métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13 BR112018072263A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328539P 2016-04-27 2016-04-27
US62/328,539 2016-04-27
PCT/US2017/029768 WO2017189805A1 (en) 2016-04-27 2017-04-27 Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies

Publications (1)

Publication Number Publication Date
BR112018072263A2 true BR112018072263A2 (pt) 2019-02-12

Family

ID=60160091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072263-4A BR112018072263A2 (pt) 2016-04-27 2017-04-27 métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13

Country Status (23)

Country Link
US (2) US11390669B2 (pt)
EP (2) EP3448391B1 (pt)
JP (4) JP6871948B2 (pt)
KR (3) KR20220147722A (pt)
CN (2) CN109562115A (pt)
AU (4) AU2017258097B2 (pt)
BR (1) BR112018072263A2 (pt)
CA (1) CA3021334C (pt)
DK (1) DK3448391T3 (pt)
EA (2) EA037960B1 (pt)
ES (1) ES2981704T3 (pt)
FI (1) FI3448391T3 (pt)
HR (1) HRP20240846T1 (pt)
IL (2) IL297519B2 (pt)
LT (1) LT3448391T (pt)
MX (2) MX2018013172A (pt)
PL (1) PL3448391T3 (pt)
PT (1) PT3448391T (pt)
RS (1) RS65652B1 (pt)
SG (1) SG11201809253RA (pt)
SI (1) SI3448391T1 (pt)
WO (1) WO2017189805A1 (pt)
ZA (2) ZA201807174B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562115A (zh) * 2016-04-27 2019-04-02 艾伯维公司 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
WO2017198148A1 (zh) * 2016-05-18 2017-11-23 上海开拓者生物医药有限公司 一种il-13抗体及其制备方法和应用
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
RU2020128551A (ru) * 2018-02-21 2022-03-21 АДЭР ФАРМАСЬЮТИКАЛЗ ЮЭс, Л.П. Способы ведения эозинофильного эзофагита

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3590766T (pt) 1985-03-30 1987-04-23
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CN103275221B (zh) 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2003533187A (ja) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
JP4063213B2 (ja) 2003-12-09 2008-03-19 カシオ計算機株式会社 光源装置及びそれを備えたプロジェクタ
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
ES2902063T3 (es) * 2006-09-08 2022-03-24 Abbvie Bahamas Ltd Proteínas de unión a interleucina-13
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
LT3037104T (lt) * 2009-10-20 2020-09-10 Abbvie Inc. Anti-il-13 antikūnų izoliavimas ir gryninimas, naudojant afininę baltymo a chromatografiją
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
CA2817380C (en) * 2010-12-16 2019-06-04 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
WO2012177945A2 (en) 2011-06-21 2012-12-27 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
WO2012178188A2 (en) 2011-06-23 2012-12-27 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
KR20160068802A (ko) * 2013-10-23 2016-06-15 제넨테크, 인크. 호산구성 장애를 진단 및 치료하는 방법
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
CN109562115A (zh) 2016-04-27 2019-04-02 艾伯维公司 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
AU2019275659A1 (en) 2020-01-02
IL262441B2 (en) 2023-06-01
CA3021334C (en) 2022-11-29
IL297519B1 (en) 2024-02-01
JP2021050204A (ja) 2021-04-01
IL297519A (en) 2022-12-01
PT3448391T (pt) 2024-06-26
AU2017258097A1 (en) 2018-11-15
ZA201807174B (en) 2021-06-30
HRP20240846T1 (hr) 2024-09-27
IL297519B2 (en) 2024-06-01
KR102460040B1 (ko) 2022-11-01
JP7124040B2 (ja) 2022-08-23
JP2024054237A (ja) 2024-04-16
US20210380674A1 (en) 2021-12-09
PL3448391T3 (pl) 2024-09-16
SI3448391T1 (sl) 2024-08-30
EA202190162A2 (ru) 2021-04-30
AU2022268294B2 (en) 2024-08-08
KR20220147722A (ko) 2022-11-03
AU2021203358A1 (en) 2021-06-24
KR20190002607A (ko) 2019-01-08
SG11201809253RA (en) 2018-11-29
EA202190162A3 (ru) 2021-11-30
US20220281968A1 (en) 2022-09-08
ES2981704T3 (es) 2024-10-10
KR20240052871A (ko) 2024-04-23
CN114617962A (zh) 2022-06-14
EP3448391A4 (en) 2019-12-18
ZA202000478B (en) 2021-10-27
MX2018013172A (es) 2019-02-21
AU2022268294A1 (en) 2022-12-15
EA201892409A1 (ru) 2019-03-29
FI3448391T3 (fi) 2024-06-19
AU2017258097B2 (en) 2019-10-24
EA037960B1 (ru) 2021-06-15
AU2021203358B2 (en) 2022-12-01
EP4276108A2 (en) 2023-11-15
JP7434456B2 (ja) 2024-02-20
EP3448391B1 (en) 2024-05-29
WO2017189805A1 (en) 2017-11-02
CA3021334A1 (en) 2017-11-02
JP6871948B2 (ja) 2021-05-19
JP2019514919A (ja) 2019-06-06
IL262441A (en) 2018-12-31
DK3448391T3 (da) 2024-06-24
CN109562115A (zh) 2019-04-02
US20230220061A1 (en) 2023-07-13
EP3448391A1 (en) 2019-03-06
LT3448391T (lt) 2024-06-25
MX2022008255A (es) 2022-08-04
EP4276108A3 (en) 2024-01-24
AU2019275659B2 (en) 2021-04-22
JP2022160627A (ja) 2022-10-19
US11390669B2 (en) 2022-07-19
RS65652B1 (sr) 2024-07-31

Similar Documents

Publication Publication Date Title
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
PH12016501120B1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
BR112018072263A2 (pt) métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
CO2017001317A2 (es) Composición farmacéutica con anticuerpos anti cd40 y kit
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
BR112018009064A2 (pt) anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
BR112017000939A2 (pt) tratamento de câncer usando um receptor antigênico quimérico de cll-1
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
BR112015021115A2 (pt) agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes
DOP2017000071A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace.
EA201592203A1 (ru) Способы лечения таупатии
EA201691521A1 (ru) Антитела к интерлейкину-21
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
WO2015100409A3 (en) Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
EA201990222A1 (ru) Антитела к o2 и пути их применения
EA201990988A1 (ru) Антитела против chikv и пути их применения
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
BR112023026111A2 (pt) Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
PH12018500445A1 (en) Use of anto-cd40 antibodies for treatment of lupus nephritis

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]